Page 5 - Functional Class News Today

Five late-breaking presentations at TCT 2022 highlight the impact of Abbotts structural heart devices to repair or replace heart valves and close openings in the heartNew data reinforce the safety...

District Court ruling was favorable on ‘066 patent and unfavorable on ‘793 patentAll patent claims asserted have been found to be either invalid or not...

11.08.2022 - Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) - Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the second quarter ended ...

DelveInsight’s pulmonary hypertension pipeline report depicts a robust space with 80+ active players working to develop...

MORRISVILLE, N.C., July 19, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board...

MORRISVILLE, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company was added as a member of the US...

MORRISVILLE, N.C., June 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the appointment of...

MORRISVILLE, N.C., June 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the appointment of Rajeev Saggar, M.D., to the position of Chief Medical

GuruFocus Article or News written by GuruFocusNews and the topic is about:

Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class,...